RecruitingPhase 1Phase 2NCT07640295

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

A Multicenter, Phase Ib/III Study to Evaluate JAB-23E73 in Combination With Nab-Paclitaxel and Gemcitabine in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Harboring KRAS Gene Alterations

Sponsor

Jacobio Pharmaceuticals Co., Ltd.

Enrollment

80 participants

Start Date

Jul 16, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JAB-23E73 tablet，nab-paclitaxel，gemcitabine for people with metastatic pancreatic ductal adenocarcinoma. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJAB-23E73 tablet，nab-paclitaxel，gemcitabine

Orally, intravenous (IV) infusion

Locations(13)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Beijing Tsinghua Changgung Hospital

Beijing, China

Hunan Cancer Hospital

Changsha, China

Harbin Medical University Cancer Hospital

Harbin, China

Jiangsu Province Hospital

Nanjing, China

Shanghai Jiaotong University School of Medicine Ruijin Hospital

Shanghai, China

ShanXi Cancer Hospital

Taiyuan, China

Hubei Province Hospital

Wuhan, China

Wuhan Union Hospital Of China

Wuhan, China

Zhongnan Hospital of Wuhan University

Wuhan, China

Henan Cancer Hospital

Zhengzhou, China

The First Affiliated hospital of Zhengzhou University

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07640295

Related Trials

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT040056901 location

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT0749030120 locations

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437214 locations

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

NCT068435511 location

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT072142981 location